The best creams for nerve pain are topical lidocaine 4–5% and topical capsaicin 8% (prescription patch) for localized neuropathic pain, with compounded creams containing gabapentin, ketamine, or amitriptyline used off-label when standard options fail. These formulations work by blocking sodium channels or depleting substance P at nerve endings, not by masking inflammation like ordinary analgesics. Evidence quality varies sharply: lidocaine has moderate support for postherpetic and diabetic neuropathy, capsaicin 8% has FDA approval for postherpetic neuralgia, while most compounded creams rest on small trials and clinical experience rather than large randomized data.
How Topical Nerve Pain Creams Actually Work
Nerve pain differs from ordinary injury pain at the receptor level. Damaged nerves fire spontaneously, and their sodium channels become hypersensitive. Topical agents exploit this by acting locally on cutaneous nerve endings, achieving high tissue concentration with roughly 5–10% of the systemic exposure a pill would produce. Per the FDA's 2007 approval of the capsaicin 8% patch (Qutenza), this near-zero systemic load is the central safety advantage.
Lidocaine blocks voltage-gated sodium channels in the skin and subcutaneous tissue. Applied at 4–5%, it stabilizes hyperexcitable C-fibers without deadening deep sensation. Capsaicin works oppositely at first: it activates TRPV1 receptors, causing a burning burst, then defunctionalizes those nerve endings by depleting substance P. The 8% patch achieves this depletion in a single 30–60 minute application, whereas lower-concentration creams require repeated dosing over weeks.
In plain terms: lidocaine numbs the misfiring nerve; capsaicin exhausts it until it stops shouting.
Quantified Context: Where Topical Treatment Fits
Topical creams are a localized tool in a condition that is usually regional or diffuse. Roughly 30–40% of patients with diabetic peripheral neuropathy achieve meaningful relief from any single topical agent, versus about 50% from systemic gabapentinoids or duloxetine in pooled trials. Combination approaches push response rates higher. The key metric is the number needed to treat: for topical lidocaine in postherpetic neuralgia, one trial reported a 50% pain reduction in about 1 of every 3 patients at two weeks.
Cost also matters. A prescription lidocaine 5% patch runs about USD 30–100 per month depending on insurance. Capsaicin 8% patch treatment costs USD 300–700 per session in the US and is administered in a clinic. Over-the-counter capsaicin 0.025–0.1% creams cost under USD 20 but require 4–6 applications daily.
Comparison of Common Topical Nerve Pain Creams
| Agent | Concentration | Best Evidence | Onset | Dosing | Typical Cost |
|---|---|---|---|---|---|
| Lidocaine | 4–5% cream or patch | Postherpetic, diabetic neuropathy (moderate) | 15–30 min | Up to 3–4 times daily | USD 30–100/month |
| Capsaicin | 0.025–0.1% OTC | Joint and localized pain (weak for neuropathy) | Days to weeks | 4–6 times daily | Under USD 20 |
| Capsaicin | 8% patch | Postherpetic neuralgia (FDA-approved 2009) | Hours | Every 12 weeks, clinic | USD 300–700/session |
| Compounded gabapentin | 6–10% | Case series only | 1–2 weeks | 2–4 times daily | USD 40–150 |
| Compounded ketamine | 2–10% | Small trials, mixed | Hours to days | 2–4 times daily | USD 50–200 |
| Amitriptyline compound | 1–5% | Very limited data | Days | 2–3 times daily | USD 40–120 |
Reconciling the ranges: the 0.025–0.1% capsaicin figure refers to over-the-counter products, while the 8% figure refers to the clinic-applied prescription patch, a roughly 80-fold concentration difference.
Body Region Considerations
Where the pain sits changes which formulation makes sense. Hands and feet tolerate patches poorly because of contours and sweat; creams and gels at 4–5% lidocaine dominate here, with the foot especially needing a vehicle that survives sock friction. Trunk and postherpetic rashes on the torso suit the 8% patch, since a flat 280 square centimeter area allows single-application coverage; typical applications use up to 4 patches per session for the feet or 1–2 for the torso.
Face and mucosal areas are high-absorbance zones. Lidocaine absorption through facial skin can nearly double versus forearm skin, so lower strength and smaller amounts apply. Never use topical anesthetics near the eye or inside the nose without specialist direction.
Timeline: How Long Each Cream Takes to Work
| Timeline | What Happens |
|---|---|
| 0–30 minutes | Lidocaine begins numbing; capsaicin causes burning (expected) |
| 1–3 days | First lidocaine relief window fully assessable |
| 1–2 weeks | OTC capsaicin cumulative effect emerges; compounded creams trialed |
| 3–4 weeks | Full trial period for most creams before judging failure |
| 12 weeks | Capsaicin 8% patch repeat interval; systemic effects reviewed |
| 3 months | Reassess if improvement under 30% pain reduction |
The rule of thumb: give any topical a full 3–4 weeks unless it causes intolerable irritation, and expect capsaicin 8% to deliver its effect within days of each application.
Misconceptions and Non-Obvious Mechanisms
The most common misconception is that a cream "treats the nerve." It does not reach the damaged nerve; it acts on nerve endings in the skin. Relief is real but confined to the treated area, which is why a cream on the foot will not help burning that extends to the calf.
A counterintuitive finding: capsaicin's initial burning is not a side effect to avoid but the mechanism itself. Patients who stop at the first burn never reach defunctionalization. Conversely, lidocaine loses potency with overuse because cutaneous sodium channels upregulate with chronic blockade; a 2019 review noted diminished response in some patients after months of daily use, a form of local tachyphylaxis.
One professional caveat: compounded creams are not FDA-approved as finished products. Their potency and stability depend entirely on the compounding pharmacy, and studies have found concentration errors of 10–20% in some samples. Ask for a pharmacy with documented quality testing.
Red Flags: When Creams Are the Wrong Tool
Bulleted warnings that signal you need medical evaluation, not a topical:
- Pain spreading rapidly beyond a localized area within days
- New weakness, foot drop, or loss of bowel or bladder control
- Skin wounds, infection, or ulceration near the pain site (avoid lidocaine on broken skin)
- Burning that persists more than 72 hours after capsaicin application
- Chest pain, palpitations, or dizziness after any topical application
- Pain after starting a new medication known to cause neuropathy
What to Actually Do
Start with a proven agent rather than a compounded mystery. For postherpetic neuralgia, ask about the capsaicin 8% patch (FDA-approved) or lidocaine 5% patch. For diabetic foot pain, trial lidocaine 4–5% cream three times daily for three weeks and log pain scores. If response is under 30%, discuss a compounded gabapentin 6% cream with a prescriber who can verify pharmacy quality.
Apply only to intact skin, no more than the labeled frequency, and never occlude with plastic wrap unless directed—occlusion can raise systemic absorption several-fold. Keep a simple log of pain score before and after each application; objective tracking beats memory when deciding whether to continue.
Limitations and the Honest Evidence Gap
Topical creams are adjuncts, not replacements for addressing the cause of neuropathy—blood sugar control in diabetes, antiviral timing in shingles, or medication review in drug-induced cases. Large randomized trials exist mainly for lidocaine and capsaicin; compounded gabapentin, ketamine, and amitriptyline rest largely on small studies, and their popularity outpaces their evidence. Per a 2020 Cochrane review, topical capsaicin at low concentration showed only low-quality evidence for neuropathic pain relief, while the 8% patch evidence was stronger but limited to specific conditions.
The bottom line: choose a cream matched to location and cause, give it a fair trial, measure the result, and treat any topical as one layer of a broader plan.